Condition: Hematologic Malignancy · Solid Tumor · Advanced Malignancies · Sponsor: Novartis Pharmaceuticals
The purpose of this study is to evaluate the long-term safety and the clinical benefit of pelabresib in patients with hematological and/or solid tumor indications or advanced malignancies. Additionally, participants previously enrolled in studies with pelabresib who received placebo or participants who discontinued pelabresib (for any other reason than participating in this extension study), may be enrolled in this extension study to evaluate the survival and leukemia-free survival (for patients with hematological malignancies) or only the Survival Follow-up (for all the other patients).
This description comes directly from the study's public registry record.
Novartis Pharmaceuticals · 1-888-669-6682 · novartis.email@novartis.com
Novartis Pharmaceuticals · +41613241111 · novartis.email@novartis.com
Always discuss trial participation with your own doctor first.
| University of California LA | Los Angeles, California, United States | Recruiting |
| Mayo Clinic Jacksonville | Jacksonville, Florida, United States | Recruiting |
| Northwestern University | Chicago, Illinois, United States | Recruiting |
| Uni Of Michigan Health System | Ann Arbor, Michigan, United States | Recruiting |
| New York Presbyterian Hospital | New York, New York, United States | Recruiting |
| Mt Sinai Medical Center | New York, New York, United States | Recruiting |
| Novartis Investigative Site | Antwerp, Belgium | Recruiting |
| Novartis Investigative Site | Bruges, Belgium | Recruiting |
| Novartis Investigative Site | Florence, FI, Italy | Recruiting |
| Novartis Investigative Site | Varese, VA, Italy | Recruiting |
| Novartis Investigative Site | Novara, Italy | Recruiting |
| Novartis Investigative Site | Amsterdam, Netherlands | Recruiting |
+ 3 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06401356